Suppr超能文献

印度镰状细胞疾病中的缺铁性贫血

Iron deficiency anaemia in sickle cell disorders in India.

作者信息

Mohanty D, Mukherjee M B, Colah R B, Wadia M, Ghosh K, Chottray G P, Jain D, Italia Y, Ashokan K, Kaul R, Shukla D K, Muthuswamy V

机构信息

National Institute of Immunohaematology ICMR, Mumbai, India.

出版信息

Indian J Med Res. 2008 Apr;127(4):366-9.

Abstract

BACKGROUND & OBJECTIVE: Iron deficiency anaemia (IDA) is uncommon in individuals with sickle cell disease (SCD) because of availability of an adequate iron source potentially from increased red cell turnover and from blood transfusions. Also, iron deficiency anaemia can often go unnoticed because the sickle cell disease patients are already anaemic. Iron deficiency in sickle cell patients may result in lowering the intracellular haemoglobin concentration and this may ameliorate sickling. The present study was undertaken to determine the prevalence of iron deficiency anaemia and the response of iron supplementation in sickle cell disorders in tribal population of the four States viz. Maharashtra, Gujarat, Orissa and Tamil Nadu.

METHODS

A total of 8434 individuals (7105 AA, 1267 AS and 62 SS) were tested for zinc protoporphyrin/haem (ZPP/H) ratio and haemoglobin levels. Twenty two sickle cell anaemia (SS), 47 sickle cell trait (AS) and 150 normal control (AA) individuals who were iron deficient, were given iron therapy for a period of 12 wk and the laboratory investigations were repeated at the 13th wk.

RESULTS

Sixty seven per cent of subjects with sickle cell anaemia and 26 per cent with sickle cell trait had elevated ZPP/H ratios (>80 micromol/mol) as against 22.8 per cent of normal individuals. The elevated ZPP/H ratios is an indicator of microcytic anaemia of iron deficiency. Following iron therapy, an improvement in the Hb levels and ZPP/H ratios was observed in both sickle cell disorders and normal individual cases.

INTERPRETATION & CONCLUSION: This study suggests that iron deficiency anaemia is an important problem in Indian sickle cell anaemia patients and iron supplementation should be given only in proven cases of iron deficiency anaemia.

摘要

背景与目的

缺铁性贫血(IDA)在镰状细胞病(SCD)患者中并不常见,这是因为潜在地可从红细胞更新增加及输血中获得充足的铁源。此外,缺铁性贫血常常未被察觉,因为镰状细胞病患者本身就贫血。镰状细胞病患者缺铁可能导致细胞内血红蛋白浓度降低,这可能会改善镰变。本研究旨在确定马哈拉施特拉邦、古吉拉特邦、奥里萨邦和泰米尔纳德邦这四个邦的部落人群中镰状细胞病患者缺铁性贫血的患病率以及补铁的反应。

方法

共对8434名个体(7105名AA型、1267名AS型和62名SS型)进行了锌原卟啉/血红素(ZPP/H)比值及血红蛋白水平检测。对22名缺铁的镰状细胞贫血(SS型)患者、47名缺铁的镰状细胞性状(AS型)患者及150名缺铁的正常对照(AA型)个体进行了为期12周的铁剂治疗,并在第13周重复进行实验室检查。

结果

镰状细胞贫血患者中有67%、镰状细胞性状患者中有26%的ZPP/H比值升高(>80微摩尔/摩尔),而正常个体中这一比例为22.8%。ZPP/H比值升高是缺铁性小细胞贫血的一个指标。铁剂治疗后,镰状细胞病患者及正常个体的血红蛋白水平和ZPP/H比值均有改善。

解读与结论

本研究表明,缺铁性贫血在印度镰状细胞贫血患者中是一个重要问题,仅应在确诊为缺铁性贫血的病例中给予补铁治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验